NEW HAVEN, Conn. & SAN DIEGO, Calif.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) (“Rallybio”) and Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Avenzo through a merger transaction (the “Merger”). Upon completion of the Merger, the combined company is expected to operate under the name Avenzo Therapeutic
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
